Although the role of the immune system in the pathogenesis of myocardial disease has been established for pathogen-driven diseases such as viral myocarditis, research more recently has focused on the cardiac inflammatory response after AMI as a risk factor for adverse remodeling. Peripheral blood monocyte counts have been linked to the development of heart failure in patients after AMI, 3 making the immune response after myocardial infarction a potential therapeutic target. High levels of presumably proinflammatory monocytes have been related to impaired infarct healing. [4] [5] [6] The underlying biological processes have mostly been studied in rodent models. 7, 8 Myocardial infarction triggers cellular and molecular changes, which attract neutrophils and inflammatory monocytes expressing high levels of the CC chemokine receptor 2 (CCR2) to the site of injury. After a few days, the injured heart switches to CX3CL1-mediated recruitment of noninflammatory monocytes. 9 The early monocyte subset expresses proinflammatory mediators and proteases for wound debridement, whereas the late subset and M2 macrophages support neoangiogenesis and extracellular matrix synthesis. 10 The emerging picture of inflammation biology positions leukocytes as both protective and harmful post AMI. An optimal repair after AMI requires a balance between coordinated cell recruitment that removes dead cell debris and strengthens the wound so that the heart performs its vital function. 11 18 F-Fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) has been used to image inflammation in multiple clinical and research settings because activated inflammatory cells show increased expression of glucose transporters and thus increased 18 F-FDG uptake. 12 For instance, imaging of macrophages using 18 F-FDG-PET has been successfully performed in atherosclerotic plaques. 13 A recent preclinical study in mice presented evidence that, under certain conditions, post-MI 18 F-FDG uptake reflects the monocytic inflammatory response in the myocardium. 14 Transient suppression of the physiologic 18 F-FDG uptake into cardiomyocytes is required to image monocytes or macrophages, which has previously been achieved in humans by low-glucose diet, fasting, and administration of heparin before PET imaging. 15, 16 Initial experience with myocardial fasting 18 F-FDG-PET in patients after AMI has been presented by us and other groups, 14, 17, 18 but the clinical relevance of this novel imaging approach has not yet been tested.
Therefore, the aim of this study was to characterize postischemic myocardium in patients with a first AMI by fasting 18 F-FDG-PET/magnetic resonance imaging (MRI) in relation to the cellular immune response and the functional outcome after 6 months.
Methods
For additional information see Materials and Methods in the Data Supplement.
Patient Sample
Eligible patients admitted to the hospital with a first AMI between May 2013 and October 2014 were prospectively enrolled in the study after percutaneous coronary intervention (PCI) and giving written informed consent. The study was approved by the local ethics committee and was performed in agreement with the Declaration of Helsinki.
Positron Emission Tomography/Magnetic Resonance Imaging
Patients were imaged 5.0±1.3 days after PCI by simultaneous PET/ MRI using a hybrid system (Biograph mMR, Siemens Healthcare GmbH, Erlangen, Germany), which allows PET imaging in combination with a detailed characterization of the infarcted heart including scar size, scar transmurality, and left ventricular (LV) function in a single examination. 17 To suppress physiological myocardial 18 F-FDG uptake, patients received a low-carbohydrate diet the day before imaging followed by a 12-hour fasting period. Unfractionated heparin (50 IU/kg body weight intravenously) was administered 30 minutes before 18 F-FDG injection. Follow-up imaging by MRI only was performed on the identical system 252±68 days after PCI.
Regional Analysis
The American Heart Association (AHA) 17-segment model 19 was applied to late gadolinium enhancement (LGE) and 18 F-FDG images aligned by the MunichHeart/m 3 p software. 20, 21 LGE transmurality 22 and 18 F-FDG uptake were visually scored for each segment with scores ranging from 0 to 4 ( Figure IB in the Data Supplement). Results were additionally analyzed for mere absence or presence of LGE or 18 F-FDG signals. Analysis was performed blinded to the respective other modality. Furthermore, the degree of wall motion abnormality in each segment was evaluated using a 5-point scale as previously described 22 : normal wall motion=0, mild to moderate hypokinesia=1, severe hypo-kinesia=2, akinesia=3, and dyskinesia=4. A functional improvement of wall motion was defined as a decrease of the wall motion score of at least 1 point score. Two experienced observers performed all analyses.
Quantitative Analysis
To determine the 18 F-FDG extent, a region grow algorithm with a threshold of 50% of the maximal uptake was performed (Syngo MMWP [workstation], Syngo TrueD [software]; Siemens Healthcare). Within this volume of interest, the average tracer uptake was derived and normalized to the lean body mass and injected tracer dose yielding standardized uptake value (SUV) mean . 23 The volume with tracer uptake above the mentioned threshold was finally expressed as %LV (LV myocardial volume derived from MRI) and defined as 18 F-FDG extent (ie, the volume of the significant 18 F-FDG signal normalized to the total myocardial volume of the LV). SUV mean in remote myocardium was determined in manually drawn regions in the myocardial wall opposing the infarct on 3 consecutive slices.
The LGE extent of the LV myocardium was determined by manual delineation on short-axis images using the MunichHeart/MR software and expressed as percentage of the LV.
Single-Photon Emission Computed Tomographic Imaging
A subgroup of patients (n=23) underwent 99m Tc-sestamibi singlephoton emission computed tomography with tracer injection before PCI and image acquisition after PCI for assessment of the area at risk. 99m Tc-sestamibi single-photon emission computed tomographic images were analyzed using MunichHeart/NM. 24, 25 The method for assessment of the area at risk (as percentage of the LV) has been described previously. 26
Blood Analysis
Blood was drawn daily for ≤6 days after admission for differential blood count, creatine kinase (and MB fraction), and troponin T. For analyses of monocyte subpopulations, blood was drawn at least once early (day 0-3) and late (day 4-6) during hospitalization. If more than one sample was available for 1 time point, average values were used. Furthermore, a differential blood count and the different monocyte subpopulations were determined at the follow-up scan.
Flow cytometry analysis was performed on a Cytomics FC 500 flow cytometer (Beckman Coulter, Brea, CA). Data were analyzed with Kaluza 1.2 Analysis Software (Beckman Coulter). Red blood cells were lysed, leukocytes stained with antihuman monoclonal fluorochrome-conjugated antibodies, and immediately analyzed by flow cytometry. After gating for CD45 and forward/side scatter, gating was performed similar to previously described strategies. Inflammatory, intermediate, and noninflammatory monocyte subsets were defined by the expression of CD14, CD16, and CCR2 ( Figure IIA in the Data Supplement). [4] [5] [6] 27 
Statistics
Results are shown as mean±SD. P values less than 0.05 were considered significant. For comparison of unmatched, continuous variables, the 2-tailed unpaired Student t test was used and the χ 2 test or the Fisher exact test (in case of small numbers) to compare nominal variables. To compare matched continuous variables, the 2-tailed paired Student t test was applied. The association between continuous variables was investigated using the Pearson correlation coefficient. A stepwise multivariable regression analysis was performed to correct for the influence by different covariates, that is, in a first step a unadjusted analysis was performed to detect associated variables (P<0.10), which then entered a subsequent multivariable analysis. 
Results

Patient Characteristics
A study flow chart is depicted in Figure 1 . In total, 49 patients were initially enrolled in the study and imaged by 18 F-FDG-PET/MRI. Ten subjects were excluded from the initial analysis. Follow-up imaging was obtained in 29 patients. For this follow-up group, initial 18 F-FDG-PET and MRI data, follow-up MRI data, leukocyte, and monocyte counts were all available. All patients were treated with statins, β-blockers, and ACE inhibitors or ARBs before 18 F-FDG-PET/MRI. The characteristics of the initial imaging sample and the different investigated subgroups are described in Table 1 .
F-FDG Uptake and Localization in Relation to LGE
LGE and 18 F-FDG uptake was observed within the infarcted myocardial region. Two different patient examples are shown in Figure 2 . In all patients, both the LGE signal intensity and the 18 F-FDG uptake intensity were at least 5 SDs higher in the ischemically compromised myocardium compared with remote myocardium (SUV mean infarct versus remote: 2.2±0.4 versus 0.7±0.2, P<0.0001; Figure IA in the Data Supplement). There was no correlation between the 18 F-FDG uptake in the postischemic myocardium and remote myocardium (r=0.25, P=0.13). The postischemic 18 F-FDG uptake in the infarct area did not correlate with pain-to-balloon (r=0.02, P=0.89), pain-to-scan (r=0.10, P=0.56), or balloon-to-scan time (r=0.01, P=0.93).
In 15 (38%) patients, microvascular obstruction was observed. There was a trend toward a higher FDG uptake in patients with microvascular obstruction, which did not reach statistic significance (2.4±0.4 versus 2.1±0.4, P=0.09).
A regional analysis showed substantial agreement for the presence or absence of LGE and 18 F-FDG uptake (κ=0.66). A detailed analysis of LGE transmurality and 18 F-FDG uptake intensity (score 0-4) still showed substantial agreement between both modalities (κ=0.63; Figure IB in the Data Supplement) and a strong correlation between the summed 18 
F-FDG and
LGE score was found (r=0.82, P<0.0001; Figure IC in the Data Supplement). High 18 F-FDG scores were significantly more often present in segments with transmural infarction when compared with segments with nontransmural infarction (generalized estimating equation: P<0.001; Figure ID in the Data Supplement). Consequently, the strongest 18 F-FDG uptake was observed in areas with most transmural LGE extent.
Quantification of 18 F-FDG Extent, LGE Extent, and Area at Risk
In the regional analysis, 18 F-FDG uptake was present in more segments than LGE (372/663 segments, 56.1% versus 292/663 segments, 44.0%, generalized estimating equation: P<0.001). Quantitative comparison of cardiac 18 F-FDG and LGE extent confirmed this finding. Although both modalities showed close correlation (r=0.78, P<0.0001; Figure 3A , left and middle), the 18 F-FDG extent (ie, the volume of the 18 F-FDG signal expressed 
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as %LV) significantly exceeded the LGE extent (33.2±16.2%LV versus 20.4±10.6%LV, P<0.0001; Figure 3A , right).
In the patient subset with 99m Tc-sestamibi single-photon emission computed tomographic imaging (sample in Figure 3B ), 18 F-FDG uptake similarly exceeded the LGE extent (35.4±18.1%LV versus 21.8±14.5%LV; P<0.0001, Figure 3C , right) and showed a high correlation with the area at risk (r=0.87, P<0.0001, Figure 3C , left). Accordingly, the area at risk was larger than the LGE extent (31.3±21.6%LV versus 21.8±14.5%LV; P<0.004), but did not differ significantly from the 18 F-FDG extent (31.3±21.6%LV versus 35.4±18.1%LV; P=0.08; Figure 3C , right).
Comparison of PET/MRI With Circulating Leukocytes and Monocytes
Both the LGE and the 18 F-FDG extent correlated with peak counts of leukocytes from peripheral blood (r=0.38, P<0.02 and r=0.47, P<0.003; Figure 4A , left and middle). Also, the 18 F-FDG and the LGE extent correlated with CCR2+ monocytes (LGE: r=0.41, P<0.02, FDG: r=0.40, P<0.02, Figure 4A , right) and with CD14 high /CD16 + (also referred to as intermediate) monocytes (LGE: r=0.53, P<0.002, 18 F-FDG: r=0.42, P<0.02; Figure 4B , middle) released early (during the first 3 days) after infarction, indicating that leukocyte and monocyte release and migration to the heart may be dependent on the infarct size. The CD14 high / CD16 − (inflammatory) and CD14 low /CD16 + (noninflammatory or reparative) monocytes released early after infarction were not significantly related to the LGE extent or the 18 F-FDG extent in our patient sample ( Figure 4B , left and right column).
Interestingly, there was no correlation between the SUV mean (ie, the mean intensity of the 18 F-FDG signal) in the postischemic myocardium and the LGE extent, initial EF, peak counts of leukocytes, or monocyte subpopulations released early after infarction ( Figure IIB and IIC in the Data Supplement).
18
F-FDG Uptake in Bone Marrow and Aorta After Myocardial Infarction
A significant correlation between the 18 F-FDG uptake intensity in the infarct and the 18 F-FDG uptake in the aorta Values are n (%) or mean±SD. CKMB indicates creatine kinase muscle-brain fraction; LAD, left anterior descending; LM, left main; LVEF, left ventricular ejection fraction; MRI, indicates magnetic resonance imaging; PCI, percutaneous coronary intervention; PET, posiitron emission tomography; RCA, right coronary artery; RCX, Ramus circumflexus; and SPECT, single-photon emission computed tomography.
*P values for patients with follow-up MRI vs patients without follow-up MRI.
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F-FDG Uptake After AMI and Functional Outcome (r=0.38, P<0.02) was found, indicating a connection between the inflammatory processes in the heart and vessels after infarction. There was no relationship, however, between the 18 F-FDG uptake in the infarct area and the bone marrow (r=0.09, P=0.61) or between the bone marrow and the aorta (r=0.20, P=0.21). 
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To further elucidate this point, correlations of the 18 F-FDG signals in the aorta and the bone marrow with peak counts of leukocytes/monocytes and with counts of monocyte subsets were investigated. The 18 F-FDG signal of the bone marrow and the aortic wall did not correlate with peak leukocyte counts or peak monocyte counts. Although counts of CD14 high /CD16 − (inflammatory) and CD14 high /CD16 + (intermediate) monocyte subsets did not correlate with the 18 F-FDG uptake in the bone marrow or the aortic wall, CD14 low /CD16 + (noninflammatory or reparative) showed an inverse correlation with the 18 F-FDG uptake in the aortic wall (r=−0.46, P<0.008).
Follow-Up MRI
The LGE extent declined between initial and follow-up imaging in almost all patients (20.0±11.2% versus 14.9±10.0%, P<0.0001; Figure IIIA in the Data Supplement). In contrast, in average there was no change in the global EF at follow-up (47.4±9.7% versus 46.4±11.8%, P=0.56; Figure IIIB in the Data Supplement). There was no correlation between the postischemic 18 F-FDG uptake in the infarct area or remote myocardium and the decrease of LGE (ΔLGE; r=0.10, P=0.62 and r=0.24, P=0.21, respectively).
As expected, the change in EF, EDV, and ESV between initial and follow-up imaging were associated with the infarct size (ΔEF: r=−0.39, P<0.05; ΔEDV: r=0.41, P<0.03; and ΔESV: r=0.59, P<0.002; Figure 5A ). No outliers were detected in the functional outcome measures (ΔEF, ΔEDV, and ΔESV). Interestingly, the change in EF, EDV, and ESV was inversely correlated to the postischemic FDG uptake (SUV mean ) in the heart 5 days after infarction (ΔEF: r=−0.47, P<0.02; ΔEDV: 
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r=0.51, P<0.007; and ΔESV: r=0.60, P<0.0008; Figure 5B ). There was no correlation between the 18 F-FDG uptake in remote myocardium and the changes in EF, ESV, or EDV (ΔEF: r=−0.29, P=0.12; ΔEDV: r=0.03, P=0.90; and ΔESV: r=0. 18, P=0.35) .
To further elucidate the significance of the postischemic 18 F-FDG uptake, a stepwise multiple regression analysis with the following factors was performed: LGE extent, 18 F-FDG extent, SUV mean , peak leukocyte count, peak monocyte count, counts of the different subsets, and the pain-to-balloon time. Only the 18 F-FDG extent, the LGE extent and the postischemic 18 F-FDG uptake (SUV mean ) showed in the preceding unadjusted analysis an association (P<0.10) with at least one of the measures of functional outcome ΔEF, ΔEDV, or A B Figure 4 . Peak leukocytes, CC chemokine receptor 2+ (CCR2+) monocytes and monocyte subpopulations in relation to late gadolinium enhancement (LGE) and 18 F-fluorodeoxyglucose ( 18 F-FDG) extent. A, Correlation between infarct size and peak leukocytes after infarction (left), 18 F-FDG extent and peak leukocytes (middle), and 18F-FDG extent and CCR2+ monocytes early after myocardial infarction (right; G/L=10 9 cells per liter). B, CD14 high CD16 − (inflammatory), CD14 high CD16 + (intermediate), and CD14 low CD16 + (reparative) monocyte subpopulations determined during the first 3 days after acute myocardial infarction in relation to the LGE extent and 18 F-FDG extent (G/L=10 9 cells/L).
ΔESV (Table 2 ). In the subsequent multivariable analysis, the SUV mean remained an independent marker for LV functional outcome independent from LGE or 18 F-FDG extent ( Table 3) .
Of the 29 patients with follow-up of MRI, a total of 493 myocardial segments (according to the AHA 17-segment model) were analyzed about wall motion abnormalities. At baseline, 247 of the analyzed segments (247/493, 50.1%) showed wall motion abnormalities with a mean wall motion abnormality score of 1.7±0.8. At follow-up, 139 segments (139/493, 28.2%) still demonstrated any wall motion abnormality and the wall motion abnormality score decreased to 1.0±1.1 (P<0.0001). Segments with an improved wall motion (160/247, 64.8%) had both a lower LGE transmurality score (1.9±1.5 versus 2.4±1.6, P=0.01) as well as a lower SUV mean 
(2.2±0.4 versus 2.4±0.4, P<0.008) compared with segments without wall motion improvement ( Figure 5C) . A multivariable regression analysis with LGE transmurality score and SUV mean as variables for the association with regional wall motion improvement demonstrated that both measures independently correlated with regional wall motion improvement (LGE: P<0.03, SUV mean : P<0.02).
Discussion
Despite advances in cardiovascular medicine, myocardial infarction and subsequent loss of cardiomyocytes still result in adverse remodeling and the development of heart failure in many patients. Although regenerative approaches aiming for cardiomyocyte replacement are still under investigation, the immune system has been identified as a key player of endogenous cardiac repair and scar formation. Different leukocytes invade the heart after ischemic injury and orchestrate the removal of cell debris, the formation of new vessels, and the turnover of extracellular matrix. Of note, both an overshooting and abolished inflammatory response after myocardial infarction seem to have deleterious effects on outcome in animal models and observational studies, leading to the concept of a parabolic relationship between inflammatory response and healing quality. 28 Pro-and anti-inflammatory monocyte and macrophage subtypes have been proposed to be balancing forces in this complex and tightly regulated process. 9, 29 Furthermore, altered levels of these cellular subtypes have been associated with impaired infarct healing in patients, 4,5 making the immune system a potential therapeutic target for the prevention of heart failure after myocardial infarction. Although several immune modulatory strategies led to an improved infarct healing in preclinical trials, most clinical pilot trials have shown less promising results to date, 30 suggesting that possibly not all patients with AMI may benefit from these therapies. A recent pilot study suggested colchicine as a beneficial anti-inflammatory agent after AMI resulting in a decreased infarct size, 31 but further studies will be needed to validate these findings. 18 F-FDG-PET/MRI has been proposed as a tool to measure the cellular immune response in the myocardium in a preclinical study in mice. 14 Successful in vivo imaging of immune cells in the heart after myocardial infarction in patients may help to guide novel therapeutic approaches. Therefore, we sought to explore the value of 18 F-FDG-PET/MRI in patients with myocardial infarction in relation to the cellular immune response and functional outcome.
Our study showed 2 key findings: (1) the size of the 18 F-FDG-PET signal and the numbers of leukocytes released to peripheral blood-particularly CD14 high CD16 + monocytes-showed a significant correlation with the size of the infarction, (2) the intensity of the 18 F-FDG-PET signal was associated with MRI measures of LV global and regional functional outcome, independent of infarction size and peripheral white blood cell counts.
The preclinical work by Lee et al 14 suggested that 18 F-FDG-PET could be used to monitor CD11b+ monocytes and macrophages in the heart. Translating this concept to the clinical setting, our study demonstrated that simultaneous cardiac 18 F-FDG-PET/MRI after myocardial infarction reproducibly labeled cells within and surrounding the infarcted myocardium. The SUV mean of the 18 F-FDG-PET signal in the infarcted area measured 5 days after myocardial infarction correlated with an increase in EDV and ESV and a decrease in EF after 6 months. These relationships were still significant when the influence of the infarction size was taken into account. No correlation was found between the 18 F-FDG uptake in remote myocardium and LV functional outcome. This lack of correlation may be attributed to the early imaging time point after MI in our study, as the infiltration of remote myocardium by inflammatory cells occurs later according to the aforementioned preclinical study. 14 The postischemic 18 F-FDG uptake in the infarct (SUV mean ) showed no correlation with infarction size, initial EF, or peripheral blood laboratory parameters, suggesting that the imaging strategy added an additional level of prognostic information. The study by Lee et al 14 showed a correlation between the FDG uptake in the infarct area and the number of CD11+ cells in the murine myocardium. At first sight, it may seem puzzling that the postischemic 18 F-FDG uptake did not correlate with peripheral blood monocyte counts in our study. However, this lack of correlation does not exclude the possibility that immune cells were labeled by 18 F-FDG, as the postischemic 18 F-FDG uptake in the myocardium is likely 
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dependent on leukocyte recruitment to the myocardium, on monocyte differentiation into different macrophage subtypes and on macrophage activation-mechanisms that are possibly independent from peripheral blood cell counts. It is likely that monocyte/macrophage recruitment into the myocardium is regulated by additional factors such as local adhesion molecule and chemokine expression, and does not passively follow blood monocyte levels. From this perspective, it seems less surprising that the postischemic 18 F-FDG uptake did not correlate with peripheral blood monocyte numbers. This lack of correlation rather demonstrates the additional value of 18 F-FDG-PET/MRI over circulating biomarkers to noninvasively measure the inflammatory state in the infarct area after myocardial infarction.
Nevertheless, the use of 18 F-FDG as a tracer for inflammatory cells has limitations. As a glucose analog tracer, 18 F-FDG is taken up by a variety of cells and has been used to monitor cardiomyocyte viability 32 and metabolism in response to hypoxia. 33 In this study, 18 F-FDG uptake of normal cardiomyocytes was suppressed by patient preparation including high-fat diet, fasting, and heparin injection before the scanmethods that have been developed to image inflammation in coronary arteries and sarcoidosis. 15, 16 However, it has not been shown whether these methods reliably suppress 18 F-FDG uptake in viable postischemic cardiomyocytes, as acutely ischemic and hibernating myocardium shifts its metabolic use of fatty acids toward glucose with depletion of glycogen stores 34 and upregulation of glucose transporters 1, 35 a state termed ischemic memory. 32, 33, 36 Nevertheless, using this technique mean SUV values in the infarcted tissue were ≈3× lower when compared with healthy remote myocardium in conventional 18 F-FDG-PET imaging, indicating that this signal is not originating from vital cardiomyocytes. 37 Another limitation of 18 F-FDG-PET is that it may not be able to distinguish between different leukocyte subpopulations that play opposing roles in the complex process of infarct healing. In the light of these limitations, it seems even more remarkable that the level of 18 F-FDG uptake in the heart after myocardial infarction could still be associated with adverse global and regional functional outcome after 6 months.
Thus, the association of a higher intensity of 18 F-FDG uptake in the infarct area with signs of adverse remodeling suggested a prevalent 18 F-FDG uptake by a cell type, which can adversely affect infarct healing if it is abundantly present or shows strong metabolic activity. Interestingly, macrophages have been shown to exhibit increased 18 F-FDG uptake in vitro in response to inflammatory cytokines as well as hypoxia. [38] [39] [40] Furthermore, we found the strongest 18 F-FDG signal in areas with most transmural LGE extent, that is, least viable myocardium, supporting the idea that the predominant fraction of the 18 F-FDG signal came from inflammatory cells in this area. This finding seems to be in line with postmortem analyses of the hearts from patients who died from myocardial infarctions, showing increasing monocyte numbers in the infarct core at 5 to 14 days after myocardial infarction. 41 The area of the myocardial 18 F-FDG uptake strongly correlated with the infarction size measured by LGE. In detail, the 18 F-FDG uptake area was slightly larger than the LGE area in most patients and more closely resembled the area at risk determined in a subset of patients by 99m Tc-sestamibi single-photon emission computed tomography with tracer injection before PCI. This is in line with the finding of a recent study, showing a close relationship between the 18 F-FDG signal extent and myocardial edema by T2-weighted cardiac MRI. 18 This may be attributed to immune cells in the border zone of the infarction, to 18 F-FDG uptake in postischemic cardiomyocytes, or to methodical differences between the imaging modalities. The peak circulating levels of leukocytes after myocardial infarction were also associated with the spatial extent of myocardial injury and 18 F-FDG uptake in our patient sample. Intermediate (CD14 high CD16 + ) monocytes mobilized during the first 3 days after AMI showed a positive correlation with infarction size and the 18 F-FDG uptake area, supporting the idea that the 18 F-FDG signal reflected mobilization and migration of monocytes to a relevant degree. Expression of CCR2 (corresponding to murine Ly-6C high ) was sufficient to identify a monocyte population correlating with infarction size, suggesting a direct neuronal or humoral pathway from the infarcted heart to the spleen and bone marrow that signals the precise demand for CCR2+ cells. This seems of particular interest in the context of recent publications that show a role of Ly-6C high monocytes in orchestrating both pro-and anti-inflammatory macrophages and track the release of these monocytes back to a subset of CCR2+ hematopoietic stem and progenitor cells in the mouse. 42, 43 The association of CCR2+ (and particularly intermediate) monocyte counts with impaired outcome after myocardial infarction in patients seems to be in line with our observation, although an association of monocytes subtypes with outcome independent of infarction size has been proposed in some studies. 5, 6 As described before, we also observed a decrease in LGE after MI between baseline imaging and 6-month follow-up. 44 Because the decline in LGE after myocardial infarction is mainly attributed to a decrease in edematous tissue, it is not surprising that no correlation with the postischemic FDG uptake in the heart was found.
AMI is a severe traumatic event that leads to immune responses in multiple organ systems. A substantial number of the monocytes initially recruited to the heart derived from a reservoir in the spleen. The first few days after infarction leukocyte recruitment remain at high levels. To meet this demand, cell production increases in the bone marrow and in the spleen. Several reports demonstrated a higher 18 F-FDG uptake within the spleen, the bone marrow, and the carotid arteries in patients with AMI compared with controls. 45 The focus of this study was to investigate the relevance of postischemic 18 F-FDG uptake in the myocardium about LV functional outcome after 6 months. Therefore-and to limit the duration in the scanner for the post-MI patients-the imaging protocol was focused to image the heart; other organs (eg, the spleen) were not fully covered in most patients and were therefore not studied. Furthermore, the inflammatory processes in spleen and bone marrow are known to follow distinct temporal dynamics, differing from the dynamics in heart. Therefore, imaging the 3 organ systems at the same time point was F-FDG Uptake After AMI and Functional Outcome not considered ideal for the analysis of their interactions. Consistently, we did not find strong relationships between circulating cells, 18 F-FDG uptake in the heart, and 18 F-FDG uptake in the bone marrow.
However, we found a correlation between the 18 F-FDG uptake in the postischemic myocardium and the aortic wall, supporting the idea that the systemic immune response after myocardial infarction may affect atherosclerosis. Interestingly, we also found a significant inverse correlation between the CD14 low /CD16 + (noninflammatory or reparative) monocyte subset and the 18 F-FDG uptake in the aortic wall, indicating a possible protective role of these cells about arterial inflammation after acute MI. However, it has to be acknowledged that the release of leukocytes and monocytes after AMI is highly dynamic and a single imaging session might not be sufficient to clarify these questions.
This study was performed using a clinical hybrid PET/ MRI. It has to be acknowledged that all obtained data could have also been acquired using separate devices (such as standalone MRI and PET or PET/CT). This would have resulted, however, in an increased complexity of the workflow (about the need for 2 independent imaging appointments) and would have increased stress and radiation dose for the patients because of the necessity of an additional scan for attenuation correction using PET/CT or standalone PET. Furthermore, data analysis would be complicated using separate scanners because ideal coregistration is only guaranteed when performing a simultaneous scan using hybrid PET/MRI. Still, it has to be pointed out that centers without access to a hybrid PET/MRI scanner may use standalone PET and MRI to further investigate this novel imaging approach.
This study has some limitations. We planned this observational study with a relatively small sample size because of the unknown variance of the readout. However, additional patients were lost to MRI follow-up. The small patient number does also not allow association with hard end points. Because of the small patient number and the explorative nature of our study, validation of our findings in a larger cohort will be necessary. The prospective nature of our study, the detailed assessment of clinical and laboratory parameters, and the inclusion of a functional follow-up are strengths of our study. The time point of imaging was extrapolated from small animal studies because serial PET imaging in patients did not seem to be justified. Serial imaging in large animals may help to optimize the timing of this novel imaging strategy.
In conclusion, the results of this study suggest that 18 F-FDG-PET/MRI may offer additional prognostic information about adverse functional outcome in patients with myocardial infarction. The paucity of beneficial results from early clinical therapeutic trials targeting the immune system in myocardial infarction may partly have been caused by an unspecific patient selection in combination with potentially harmful side effects. We think that this imaging approach may be able to identify patients at risk for an excessive immune response who are more likely to benefit from immune modulatory therapies that target specific cell subsets. Furthermore, PET/MRI could be used to monitor and guide these therapies, particularly in clinical trials. Taken together, there is an accumulating evidence from ours and other studies that fasting
